Esperion Therapeutics to Present at Bank of America Merrill Lynch Smid Cap and BioCentury Future Leaders in the Biotech Industry Conferences
Esperion Therapeutics to Present at Bank of America Merrill Lynch Smid Cap and BioCentury Future Leaders in the Biotech Industry Conferences
March 12, 2015
Bank of America Merrill Lynch Smid Cap Conference 2015 inBoston, MA onWednesday, March 18, 2015 at11:45 a.m. Eastern Time .- 22nd
Annual BioCentury Future Leaders in the
Biotech Industry Conference inNew York City onFriday, March 20, 2015 at11:00 a.m. Eastern Time .
A live, listen-only webcast of the
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.
About
Media Contact:
212.257.6724
efox@w2ogroup.com
Investor Contact:
734.887.3903
mlowe@esperion.com
Source:
News Provided by Acquire Media